

MAXIMIZE CLOT RETENTION

MIRCO-FILTRATION
TECHNOLOGY DESIGNED TO



UNIQUELY DESIGNED WITH
DROP ZONE™ TECHNOLOGY TO
CAPTURE CLOT INSIDE
THE DEVICE

DESIGNED FOR **FIRST-PASS SUCCESS**
WITH **ALL CLOT TYPES**



DROP ZONE THE CLOT INSIDE

Product Number	Description	Diameter (mm)	Working Length (mm)	Total Basket Length (mm)	Push-wire Length (mm)	Number of Drop Zones	Minimum MC ID (Inches)
30020V-MS	NeVa 4.0 x 22 mm	4.0	22	39	180	2	0.021

NeVa™



VN-4529-03RR	NeVa 4.5 x 29 mm	4.5	29	46	180	3	0.021
--------------	------------------	-----	----	----	-----	---	-------

NeVa™



VN-5537-03RR	NeVa 5.5 x 37 mm	5.5	37	56	180	3	0.027
--------------	------------------	-----	----	----	-----	---	-------

NeVa™




VN-5537-03NR	NeVa NET 5.5 x 37 mm	5.5	37	56	180	3	0.027
--------------	----------------------	-----	----	----	-----	---	-------

NeVa NET




IMPRESSIVE FIRST PASS SUCCESS¹

SUCCESSFUL FIRST PASS RECANALIZATION:
PERCENTAGE OF eTICI 2B-3 IN THE CLEAR STUDY
(mITT, n = 107)



EXCELLENT FIRST PASS RECANALIZATION:
PERCENTAGE OF eTICI 2C-3 IN THE CLEAR STUDY
(mITT, n = 107)



1. Core-lab adjudicated results from FDA-regulated IDE study NeVa CLEAR presented by Yoo A, et al. abstract 4311, ISC, Feb. 2023

HIGH EFFICACY DESIGN AGNOSTIC TO CLOT MORPHOLOGY^{2,4}

SUCCESSFUL IN REMOVING ALL CLOT TYPES²

NEVA RECANALIZATION RATES IN DIFFERENT CLOT MORPHOLOGIES



SUCCESSFUL WHERE OTHER DEVICES FAIL^{3,4}

SUCCESS RATE OF STENT RETRIEVERS WHEN INTERACTING WITH LARGE WHITE THROMBI (≥ 6MM)

ALL TESTED DEVICES FAILED³

Solitaire*
Trevor
Embotrap
Preset*
Preset LT
Catch*
Eric
Separator 3D
...**

NEVA SUCCEEDED⁴


0% 60%

*These devices were able to minimally displace clots without removing them
**The list of devices that failed to remove large white thrombi is incomplete


2. Results from animal model study: Uhm A.J. et al. Interventional Neurology 2018 ; 7 :205-207
3 & 4. Results from in-vitro simulated thrombectomy studies: 3. Machi P, et al. JNIS. 2016; 01-7 and 4. Machi P, et al. Journal of Neuroradiology. April 2018

PROVEN SAFETY¹

COMPOSITE ENDPOINT OF 90-DAY ALL-CAUSE MORTALITY AND/OR 24-HOUR POST-PROCEDURE sICH (ITT, n = 139)



SIGNIFICANT CLINICAL OUTCOMES (90-DAY mRS ≤ 2) IN THE CLEAR STUDY VERSUS PREDICATE STUDIES (mITT, n = 107)




1. Results from FDA-regulated IDE study NeVa CLEAR presented by Yoo A, et al. abstract 4311, ISC, Feb. 2023

MAXIMIZED RETENTION, MAXIMIZED REPERFUSION NeVa NET

SIGNIFICANTLY BETTER AT PREVENTING CLOT FRAGMENTS FROM EMBOLIZING DISTAL TERRITORIES^{5,6}

CLOT FRAGMENTS GENERATED⁵




FREQUENCY OF LARGE EMBOLI GENERATED⁶

28% LESS FRAGMENTS >1mm generated versus Solitaire
P=0.003

24% LESS FRAGMENTS >1mm generated versus Embotrap 2
P=0.003

TOTAL AREA OF EMBOLI GENERATED⁶



Results from randomized, in-vitro simulated thrombectomy studies: 5. Vania et al. JVIN, Feb 2023, 6. Li et al. JNIS, May 2023